Probi

Probi's report for the first quarter 2024 will be published on Tuesday, 18 April at 8.00 a.m. CET.

In conjunction with this, analysts, investors and media are invited to an audiocast telephone conference on the same day at 10.00 a.m., where CEO Anita Johansen and CFO Per Lindblad will present and comment on the report. The presentation and presentation material can be obtained via www.probi.com or https://ir.financialhearings.com/probi-q1-report-2024

If you wish to participate via webcast, please use the link below. Via the webcast you are able to ask written questions. https://ir.financialhearings.com/probi-q1-report-2024

If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference. https://conference.financialhearings.com/teleconference/?id=50049162

An on-demand version of the presentation will be available at the address given above following the presentation.

For further information, please contact:

Per Lindblad, CFO, Probi, phone +46 46 286 89 41, E-mail: per.lindblad@probi.com

ABOUT PROBI
Probi^® is a global Group that focuses exclusively on research, manufacturing and delivery of probiotics in dietary supplements and food. The company has expertise in managing live bacteria from research through all stages of the manufacturing process and is dedicated to making the health-promoting benefits of probiotics available to people around the world. Since the company was founded in 1991 at Lund University in Sweden, Probi has expanded its operations to more than 40 markets and holds more than 400 patents worldwide. Probi had sales of SEK 628 m in 2023. Probi's shares are listed on Nasdaq Stockholm, Mid-cap, and there were around 3,400 shareholders on December 31, 2023.